Combination of cyclin-dependent kinase 4/6 inhibitors and renin-angiotensin system inhibitors in breast cancer treatment: a promising therapeutic approach

Emel Mutlu, Mevlüde İnanç · 2025

Read Combination of cyclin-dependent kinase 4/6 inhibitors and renin-angiotensin system inhibitors in breast cancer treatment: a promising therapeutic approach by Emel Mutlu, Mevlüde İnanç (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12711125.txt.

Description

Emel Mutlu and Mevlüde İnanç test whether common blood pressure drugs quietly boost a modern breast cancer therapy. CDK4/6 inhibitors have improved outlooks in metastatic breast cancer. Renin-angiotensin system blockers, taken widely for hypertension and heart failure, may also starve tumors by trimming their blood vessel growth. Their 2025 study reviews records of metastatic patients on CDK4/6 therapy.

Patients are split by whether they also took one of the blood pressure drug classes. Outcomes are compared across the groups, looking for a synergy the lab rationale predicts. The approach is cheap pharmacology: both drug families are generic, familiar, and already sitting in many patients' cabinets. Oncologists get early clinical evidence for a pairing born from a side observation.

Catalog record

CREATOREmel Mutlu, Mevlüde İnanç
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE20 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12711125

Browse the full library · About the Tower of Babel